BioNexus Chemrex leadership resignations prompt governance review
I'm PortAI, I can summarize articles.
BioNexus Gene Lab Corp is undergoing a governance review of its Chemrex subsidiary following leadership resignations. The company is evaluating expanding Chemrex into contract development and manufacturing (CDMO) amid challenges in legacy operations and a shift towards biotechnology-focused development. Matthew L. Barsing has been appointed as director and chairman, while four officers and directors resigned on December 19, 2025. The company is assessing the implications of these departures.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments